Journal «Angiology and Vascular Surgery» • 

2000 • VOLUME 6 • №3

THE POTENTIAL OF TICLOPIDINE TO MAINTAIN REVASCULARIZATION EFFECT IN PATIENTS WITH PERIPHERAL ARTERIOSCLEROSIS

A.A. Kirichenko, V.I. Prekina, T.N. Zverkhanovskaya, N.A. Malinina, G.A. Levina

The aim of the study was to assess hemostasis parameters and effectiveness of Ticlopidine in maintaining the effect of radioendovascular revasculariwtion in patients with peripheral arteriosclerosis. Ticlopidine (ticlid) inhibits platelet adhesion and aggregaton. The study included 69 patients aged from 42 to 67 with peripheral arteriosclerosis and Fontain stage II ischemia. All patients underwent successful limb radioendovascular revascularitation. Thirty six patients from the test group received Ticlopidine (250 mg twice a day) 3-5 days preoperatively and in the same dose 4-22 months after revasculariwtion procedure. Control group included 33 patients who received Aspirin 500 mg daily. All patients underwent angiography; anklebrachial index was measured by Doppler sonography before and 1 day after procedure, 2 weeks, 1, 3 months and further each 3 months. In the test group antiaggregatory effect has been maintained through the whole therapy period. Comparative analysis of hemostasis data in 2 groups revealed that Ticlopidine decreased spontaneous and ADP-induced platelet aggregation and facilitated disaggregation thus reducing the risk of thrombosis in patients with peripheral arteriosclerosis.

KEY WORDS: ticlopidine, interventional radiology, peripheral arteriosclerosis.

P. 16

« Back

Angiologia.ru - portal for professionals
VLAANT
Lancet
HI-TECHNOLOGY MEDICINE